Anant Narayan Bhatt (Anant N Bhatt)

Years Active: 2019-2024
Publications (10 Years): 5

DRDO Institute of Nuclear Medicine and Allied Sciences

Central Drug Research Institute (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

DRDO Institute of Nuclear Medicine and Allied Sciences Mar 29 2005

India

Scientist E

Education History

Central Drug Research Institute Jan 15 2001 - Jun 30 2006

India

PHD :: Molecular and Structural Biology

Dr Ram Manohar Lohia Avadh University Jul 01 1998 - Jun 30 2000

India

MSC :: Biochemistry

Deen Dayal Upadhyay Gorakhpur University Jul 01 1994 - Jun 30 1997

India

BSC :: Biology

Publications

Abhishek Kumar, Dhananjay K Sah, Yogesh Rai, Amit K Yadav, Pratima R Solanki, Mohd Saquib Ansari, Anant Narayan Bhatt
Granular Hemostatic Composite of Alginate, Calcium, and Zinc for Rapid and Effective Management of Post-Traumatic Hemorrhage. ACS applied materials & interfaces 16 (8) (2024)
Abhishek Kumar, Dhananjay K Sah, Yogesh Rai, Amit K Yadav, Pratima R Solanki, Mohd Saquib Ansari, Anant Narayan Bhatt
Granular Hemostatic Composite of Alginate, Calcium, and Zinc for Rapid and Effective Management of Post-Traumatic Hemorrhage. ACS applied materials & interfaces (2024)
Abhishek Kumar, Dhananjay K Sah, Yogesh Rai, Amit K Yadav, Pratima R Solanki, Mohd Saquib Ansari, Anant Narayan Bhatt
Granular Hemostatic Composite of Alginate, Calcium, and Zinc for Rapid and Effective Management of Post-Traumatic Hemorrhage. ACS applied materials & interfaces 16 (8) (2024)
Anant Narayan Bhatt, Srinivas Shenoy, Sagar Munjal, Vijayakumar Chinnadurai, Apurva Agarwal, A Vinoth Kumar, A Shanavas, Ratnesh Kanwar, Sudhir Chandna
2-deoxy-D-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial. BMC infectious diseases 22 (1) (2022)
Yogesh Rai, Priyanshu Yadav, Neeraj Kumari, Namita Kalra, Anant Narayan Bhatt
Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin. Bioscience reports 39 (9) (2019)

Anant Narayan Bhatt.css-eqlu8i{font-size:small;padding-left:4px;} (Anant N Bhatt)